Efficacy of Lianhua Qingwen in Treating Patients Infected With the Omicron Variant of the COVID-19

Qianfoshan Hospital200 enrolled

Overview

A retrospective analysis was conducted on patients infected with the Omicron variant of COVID-19 diagnosed from August 2022 to now. Patients were divided into observation groups and control groups according to whether or not oral Lianhua Qingwen granules were used. Through data analysis and follow-up, the effectiveness of Lianhua Qingwen in treating patients infected with the Omicron variant of COVID-19 was discussed.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

COVID-19 Pneumonia

Interventions

The group of patients who received Lianhua Qingwen orallyDRUG

Lianhua Qingwen Granules: oral. One bag at a time, three times a day. The course of treatment for mild and ordinary cases of novel coronavirus pneumonia is 7-10 days.

The group of patients who did not receive Lianhua Qingwen orallyOTHER

The group of patients who did not receive Lianhua Qingwen orally.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * For patients infected with the Omicron variant, the diagnostic criteria are confirmed cases of COVID-19 and clinical classification according to the diagnostic criteria of Prevention and Control Protocol for COVID-19 (Trial Eighth Edition) issued by the National Health and Construction Commission. * The clinical symptoms were classified as mild or ordinary. * They have been vaccinated against the COVID-19. Exclusion Criteria: * Patients receiving antiviral or antibiotic drugs * Severe and critical patients with COVID-19. * Patients with chronic respiratory diseases, bacterial infections of the respiratory system, and other respiratory diseases affecting the study. * Patients with serious primary diseases of the heart, brain, lung, liver, kidney, and hematopoietic systems, as well as mental diseases. * Allergic reaction to Lianhua Qingwen granules. * Excluded patients treated with the same drug as Lianhua Qingwen.

Locations (1)

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China

Jinan, Shandong, China

RECRUITING

Outcomes

Primary Outcomes

Disappearance rate of symptoms

Disappearance rate of symptoms (fever, fatigue, cough)

Time frame: two weeks

Central Contacts

Qian Qi, Dr.

CONTACT

+86 13706380314 qiqianqlh@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.